Symposia: Cellular Immunotherapies: Basic and Translational
Oral and Poster Abstracts
Oral
Research, Lymphoid Leukemias, Biological therapies, Fundamental Science, ALL, Translational Research, Lymphomas, Plasma Cell Disorders, Chimeric Antigen Receptor (CAR)-T Cell Therapies, Combination therapy, B Cell lymphoma, drug development, Diseases, Gene Therapy, immune mechanism, Therapies, Immunotherapy, immunology, Lymphoid Malignancies, Adverse Events, Biological Processes, Natural Killer (NK) Cell Therapies, Technology and Procedures, gene editing
388-390
(Ernest N. Morial Convention Center)
Moderators:
Zachary D. Crees, MD, Washington University School of Medicine
and
Katherine D Cummins, PhD, BMBS, Peter MacCallum Cancer Centre
Disclosures:
Crees: BioLineRx Ltd.: Research Funding.
This session focuses on cell- and genetherapy at its early stage of development with a clear link to the clinical need. Focus is on the improvement of gene-modified effector cells by overcoming immune escape and rejection, increasing persistence and limiting toxicity. However, it is not limited to CAR T cells only and contains even broader approaches such as the regulatory role of the thymus, the tumor microenvironment as well as the recruitment of bystander immunity, all prerequisites of long lasting clinical responses.
9:30 AM
Quirin Hammer, PhD1*, Karlo Perica, MD, PhD2*, Rina M Mbofung, PhD3*, Hanna van Ooijen4*, Erika Varady3*, Mark Jelcic3*, Yijia Pan, PhD3*, Pouria Momayyezi, MD5*, Brian Groff, BS3*, Ramzey Abujarour, PhD3*, Silje Zandstra Krokeide6*, Tom Lee, PhD3*, Alan M Williams, PhD3*, Jode P Goodridge7*, Bahram Valamehr7, Bjorn Onfelt, PhD4*, Michel Sadelain, MD, PhD8 and Karl-Johan Malmberg5,6*
1Center for Infectious Medicine, Department of Medicine, Huddinge, Karolinska Institute, Huddinge, Sweden
2Memorial Sloan Kettering Cancer Center, New York, NY
3Fate Therapeutics Inc., San Diego, CA
4The Royal Institute of Technology, Stockholm, Sweden
5Center for Infectious Medicine, Department of Medicine, Huddinge, Karolinska Institute, Stockholm, Sweden
6Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway
7Fate Therapeutics, Inc., San Diego, CA
8Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY
9:45 AM
Ulrike Gerdemann, MD1,2, James Kaminski1,3*, Ryan A Fleming1*, Victor Tkachev, PhD1,2, Francesca Alvarez Calderon, MD, PhD1,2, Connor McGuckin1*, Xianliang Rui, PhD4*, Jennifer Lane, DVM1*, Alex K. Shalek, PhD5,6,7* and Leslie Kean, MD, PhD1,2
1Division of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston
2Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston
3Broad Institute of MIT and Harvard, Cambridge
4Division of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, MA
5Ragon Institute of Massachusetts General Hospital (MGH), MIT and Harvard, Cambridge, MA
6Broad Institute of MIT and Harvard, Cambridge, MA
7Department of Chemistry, Institute for Medical Engineering and Science (IMES), and Koch Institute for Integrative Cancer Research, Cambridge, MA
10:00 AM
Mehmet Emrah Selli, PhD1*, Jack Landmann2*, John Lattin3*, Amanda Heard1*, John Warrington1*, Helen Ha1*, Jufang Chang, PhD1*, Natalie Kingston4*, Graham Hogg1*, Mark Foster5*, Samantha Kersting-Schadek6*, Marina Terekhova1*, David DeNardo1*, Todd A. Fehniger, MD, PhD7, Maxim Artyomov1* and Nathan Singh, MD1
1Washington University School of Medicine, Saint Louis, MO
2Washington University School of Medicine, Saint Louis
3Saint Louis University School of Medicine, St Louis
4Washington University, Saint Louis, MO
5Department of Medicine, Washington University, St Louis, MO
6Washington University School of Medicine, St Louis, MO
7Division of Oncology, Washington University School of Medicine, St. Louis, MO
10:15 AM
Jeremie Martinet1,2,3*, Mayumi Sugita, MD3, Mohammad Alhomoud, MD3, Catalina Abad4*, Gabriela Chiosis, PhD5*, Gail J. Roboz, MD6, Olivier Boyer, MD, PhD1,7 and Monica L. Guzman, PhD3
1University of Rouen Normandy, Inserm, U1234, F-76000, Rouen, France
2Rouen university hospital, Department of immunology and biotherapy, F-76000, Rouen, France
3Division of Hematology and Oncology, Department of Medicine, Weill Cornell Medicine/New York Presbyterian Hospital, New York, NY
4Inserm U1234, University of Rouen Normandy, Rouen, France
5Chemical Biology Program, Memorial Sloan Kettering Cancer Center, New York, NY
6Division of Hematology and Oncology, Weill Cornell Medicine and The New York-Presbyterian Hospital, New York, NY
7Rouen university hospital, Department of immunology and biotherapy, F-76000, Rouen, Normandy, France
10:30 AM
Xiaomeng Hu, PhD1*, Pascal Beauchesne2*, Karl Manner3*, Corie Gattis, BA4*, Priscilla Ngo5*, Rowena De Jesus3*, Chi Young1*, Frank Wells5*, Lindong Weng3*, Kathy White, BS4*, William E Dowdle3*, Aaron Foster6, Terry Fry5* and Sonja Schrepfer7*
1Sana Biotechnology, San Francisco, CA
2Sana Biotechnology, Seattle
3Sana Biotechnology, South San Francisco
4Sana Biotechnology Inc, San Francisco, CA
5Sana Biotechnology Inc, South San Francisco
6Sana Biotechnology Inc., Houston, TX
7Sana Biotechnology Inc, San Mateo, CA
10:45 AM
Payal Goala, PhD1,2*, Hiroshi Kotani, MD, PhD3*, Zhang Yongliang4*, Kayla M. Reid, M.S.2,5*, Justin C. Boucher, PhD2, Constanza Savid-Frontera, PhD6, Sae Bom Lee7*, Nolan Beatty7*, Michael D. Jain, MD, PhD8 and Marco L. Davila, MD, PhD9
1Cell Biology, Microbiology and Molecular biology (CMMB), University of South Florida, Tampa, FL
2Division of Clinical Science, Moffitt Cancer Center, Tampa, FL
3Department of Medical Oncology, Cancer Research Institute of Kanazawa University, Kanazawa, FL, Japan
4Biovance Biotherapeutics, Tampa, FL
5Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
6Moffitt cancer center, Tampa, FL
7Clinical Science Division, Moffitt Cancer Center, Tampa, FL
8Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center, Tampa, FL
9Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL
*signifies non-member of ASH
denotes an abstract that is clinically relevant.
denotes that this is a recommended PHD Trainee Session.
denotes that this is a ticketed session.